Furthermore, combination of AZD1775 and the IRE1α inhibitor MKC8866 show remarkable synergistic effect in multiple TP53‐mutant cell lines and patient‐derived xenograft (PDX) models of ovarian cancer. This evidence concerns the gene ERN1 and ovarian carcinoma.